VISTA-mediated immune evasion in cancer
RJ Zhang, TK Kim - Experimental & Molecular Medicine, 2024 - nature.com
Over the past decade, V-domain immunoglobulin suppressor of T-cell activation (VISTA) has
been established as a negative immune checkpoint molecule. Since the role of VISTA in …
been established as a negative immune checkpoint molecule. Since the role of VISTA in …
Small Molecule Inhibitors Targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for Cancer Immunotherapy (2020-2024)
B Cheng, J Lv, Y Xiao, C Song, J Chen… - European Journal of …, 2024 - Elsevier
Cancer immunotherapy, leveraging antibodies, excels in targeting efficacy but faces hurdles
in tissue penetration, oral delivery, and prolonged half-life, with costly production and risk of …
in tissue penetration, oral delivery, and prolonged half-life, with costly production and risk of …
A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy
M Peng, X Lu, J Guo, X Yin, J Zhang, X Li, Y Zou - Biomarker Research, 2024 - Springer
Immune checkpoints are crucial for regulating immune responses and maintaining self-
tolerance, as they play a pivotal role in preventing autoimmunity and facilitating tumor …
tolerance, as they play a pivotal role in preventing autoimmunity and facilitating tumor …
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia
Introduction Acute myeloid leukemia (AML) is a complex and heterogeneous disease
characterized by an aggressive clinical course and limited efficacious treatment options in …
characterized by an aggressive clinical course and limited efficacious treatment options in …
[HTML][HTML] VISTA in hematological malignancies: a review of the literature
Y Duan, X Ren, X Guo, J Xie, Z Liu… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
In recent years, tumor immunotherapy has become an active research area, with the
emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical …
emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical …
VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations
T Yin, MH Kramer, M Bern, N Helton, D George… - Blood, 2024 - Elsevier
In an immunocompetent host, cancer cells must overcome the immune response to develop
into a clinically recognizable tumor. Although “tumor immune escape” mechanisms have …
into a clinically recognizable tumor. Although “tumor immune escape” mechanisms have …
Pathogenesis and inflammaging in myelodysplastic syndrome
MT Villaume, MR Savona - Haematologica, 2020 - haematologica.org
Myelodysplastic syndromes (MDS) are a genetically complex and phenotypically diverse set
of clonal hematologic neoplasms that occur with increasing frequency with age. MDS has …
of clonal hematologic neoplasms that occur with increasing frequency with age. MDS has …